Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Moulder · SciRah

Researcher profile · Semantic Scholar

S. Moulder

Share profile

S. Moulder — researcher profile on SciRah

h-index: 55
Works: 383
Citations: 15K

Most-cited papers

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. McGrail, P. Pilié, N. Rashid, L. Voorwerk +12 more
2021Annals of Oncology917 citations Open access
Semantic Scholar
Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes
Ruli Gao, S. Bai, Y. Henderson, Yi-Yun Lin +13 more
2021Nature Biotechnology779 citations Open access
Semantic Scholar
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
E. Mayer, A. Dueck, Miguel Martín, G. Rubovszky +40 more
2021The Lancet Oncology214 citations
Semantic Scholar
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
D. Yee, A. DeMichele, C. Yau, C. Isaacs +75 more
2020JAMA Oncology210 citations Open access
Semantic Scholar
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
J. Litton, M. Scoggins, K. Hess, B. Adrada +15 more
2020Journal of Clinical Oncology174 citations Open access
Semantic Scholar
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
T. Reddy, R. Rosato, Xiao-Xian Li, S. Moulder +2 more
2020Breast Cancer Research158 citations Open access
Semantic Scholar
Phase I/II trial of triplet therapy (exemestane, ribociclib, and everolimus) after progression on a CDK4/6 inhibitor in HR+/HER2– advanced breast cancer (TRINITI-1)
A. Bardia, S. Hurvitz, A. DeMichele, A. Clark +10 more
2021Clinical Cancer Research97 citations Open access
Semantic Scholar
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
A. Clark, C. Yau, D. Wolf, E. Petricoin +47 more
2021Nature Communications73 citations Open access
Semantic Scholar
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
Hua Guo, Q. Ding, Yun Gong, M. Gilcrease +11 more
2020Breast Cancer Research57 citations Open access
Semantic Scholar
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
F. Batalini, S. Moulder, E. Winer, H. Rugo +2 more
2020JCO Precision Oncology44 citations Open access
Semantic Scholar
Impact of TP53 mutations in Triple Negative Breast Cancer
Z. Mitri, N. Abuhadra, S. Goodyear, E. Hobbs +3 more
2022npj Precision Oncology43 citations Open access
Semantic Scholar
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Yu-Yi Chu, C. Yam, Mei-Kuang Chen, Li-Chuan Chan +15 more
2020American Journal of Cancer Research43 citations
Semantic Scholar
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
E. Dumbrava, S. G. Call, H.-J. Huang, A. Stuckett +17 more
2021ESMO Open42 citations Open access
Semantic Scholar
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA
Jennifer H. Chen, Sridevi Addanki, Dhruvajyoti Roy, Roland L. Bassett +17 more
2024BMC Cancer35 citations Open access
Semantic Scholar
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer
Vrutant V. Shah, Aundrietta D. Duncan, Shi-Ming Jiang, S. Stratton +29 more
2021Nature Communications35 citations Open access
Semantic Scholar
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
J. E. Jimenez, Abeer H. Abdelhafez, E. Mittendorf, N. Elshafeey +15 more
2022European Journal of Radiology33 citations
Semantic Scholar
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Xiao Huang, Q. Ding, Hua Guo, Yun Gong +11 more
2020Human Pathology31 citations
Semantic Scholar
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
D. Yee, C. Isaacs, D. Wolf, C. Yau +51 more
2021npj Breast Cancer28 citations Open access
Semantic Scholar
Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer
Benjamin C. Musall, Abeer H. Abdelhafez, B. Adrada, R. Candelaria +24 more
2021Journal of Magnetic Resonance Imaging27 citations Open access
Semantic Scholar
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
B. Lim, S. Seth, C. Yam, Lei Huo +27 more
2024Cell Reports Medicine26 citations Open access
Semantic Scholar
Early Ultrasound Evaluation Identifies Excellent Responders to Neoadjuvant Systemic Therapy in Patients with Triple Negative Breast Cancer
B. Adrada, R. Candelaria, S. Moulder, A. Thompson +11 more
2021Cancer25 citations Open access
Semantic Scholar
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
C. Yam, G. Rauch, T. Rahman, M. Karuturi +15 more
2020Investigational new drugs24 citations
Semantic Scholar
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
R. Candelaria, D. Spak, G. Rauch, L. Huo +15 more
2021Academic Radiology19 citations Open access
Semantic Scholar
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression
T. Reddy, Akshjot Puri, Liliana Guzman-Rojas, Christoforos Thomas +23 more
2024Nature Communications17 citations
Semantic Scholar
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
N. Abuhadra, R. Sun, C. Yam, G. Rauch +26 more
2023Cancers17 citations Open access
Semantic Scholar
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
Abeer H. Abdelhafez, Benjamin C. Musall, B. Adrada, K. Hess +23 more
2020Breast Cancer Research and Treatment16 citations Open access
Semantic Scholar
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer
R. Powell, Abena B. Redwood, Xuan Liu, Lei Guo +20 more
2020Scientific Reports16 citations Open access
Semantic Scholar
Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer
C. Yam, N. Abuhadra, R. Sun, B. Adrada +23 more
2022Clinical Cancer Research15 citations Open access
Semantic Scholar
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Xuan-Ping Liu, Zhong-Qi Ge, Fei Yang, A. Contreras +10 more
2022npj Breast Cancer15 citations Open access
Semantic Scholar
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
N. Abuhadra, R. Sun, J. Litton, G. Rauch +25 more
2022Cancers15 citations Open access
Semantic Scholar
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
C. Yam, E. Mittendorf, H. Garber, R. Sun +21 more
2023Breast Cancer Research and Treatment14 citations
Semantic Scholar
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer
G. Echeverria, Shirong Cai, Y. Tu, Jiansu Shao +23 more
2023npj Breast Cancer14 citations Open access
Semantic Scholar
Quantitative Apparent Diffusion Coefficients from Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Benjamin C. Musall, B. Adrada, R. Candelaria, Rania M. M. Mohamed +24 more
2022Journal of Magnetic Resonance Imaging14 citations Open access
Semantic Scholar
Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
N. Abuhadra, S. Stecklein, Priyanka Sharma, S. Moulder
2022The Oncologist13 citations Open access
Semantic Scholar
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer
Reid T. Powell, Amanda L. Rinkenbaugh, Lei Guo, Shirong Cai +14 more
2024npj Breast Cancer10 citations Open access
Semantic Scholar
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
B. Lim, S. Seth, L. Huo, R. Layman +16 more
20209 citations
Semantic Scholar
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
C. Yam, M. Patel, Holly Hill, Ryan Sun +35 more
2024Cancer Research Communications8 citations Open access
Semantic Scholar
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes
R. Basho, Li Zhao, J. White, Lei Huo +17 more
2024JCO Precision Oncology8 citations
Semantic Scholar
Ecotypes of triple-negative breast cancer in response to chemotherapy
Yun Yan, Yi-Yun Lin, T. Kumar, S. Bai +19 more
2026Nature7 citations Open access
Semantic Scholar
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
T. Iwase, Evan N Cohen, Hui Gao, Angela Alexander +17 more
2024Clinical Cancer Research7 citations
Semantic Scholar
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens
Hui Chen, Qing-Qing Ding, Laila Khazai, Li Zhao +30 more
2023Therapeutic Advances in Medical Oncology6 citations Open access
Semantic Scholar
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer
M. Guirguis, B. Adrada, C. Yam, D. Tripathy +26 more
2025npj Breast Cancer5 citations Open access
Semantic Scholar
Midtreatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple Negative Breast Cancer
R. Candelaria, B. Adrada, Deanna L. Lane, G. Rauch +11 more
2022Ultrasound in Medicine and Biology5 citations Open access
Semantic Scholar
Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations
S. Damodaran, J. Litton, K. Hess, Colleen T. Eppig +10 more
20205 citations
Semantic Scholar
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy
Amanda L. Rinkenbaugh, Yuan Qi, Shirong Cai, Jiansu Shao +20 more
2025Cancer Research4 citations
Semantic Scholar
Imaging and Tumor Biomarkers based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
B. Adrada, M. Guirguis, Lei Huo, C. Yam +24 more
2025JCO Precision Oncology4 citations
Semantic Scholar
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
N. Abuhadra, R. Sun, Roland L. Jr Bassett, L. Huo +25 more
2023Investigational new drugs4 citations
Semantic Scholar
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients
R. Candelaria, B. Adrada, K. Hess, L. Santiago +12 more
2020European Journal of Radiology4 citations Open access
Semantic Scholar
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
N. Abuhadra, Chia-Chi Chang, C. Yam, J. White +16 more
20213 citations
Semantic Scholar
Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
C. Yam, E. Mittendorf, R. Sun, L. Huo +16 more
20213 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. White×30
Invite
J. White — researcher profile on SciRah
J. Litton×24
Invite
J. Litton — researcher profile on SciRah
C. Yam×23
Invite
C. Yam — researcher profile on SciRah
R. Candelaria×22
Invite
R. Candelaria — researcher profile on SciRah

×21

Invite

B. Adrada — researcher profile on SciRah

Invite

G. Rauch — researcher profile on SciRah

E. Ravenberg×19

Invite

E. Ravenberg — researcher profile on SciRah

Invite

W. Symmans — researcher profile on SciRah

Invite

V. Valero — researcher profile on SciRah

Invite

L. Huo — researcher profile on SciRah

S. Damodaran×14

Invite

S. Damodaran — researcher profile on SciRah

D. Tripathy×14

Invite

D. Tripathy — researcher profile on SciRah